Biotechnology Today
more-
As esophageal cancer incidence rises, trials and potential treatments burgeon: Novotech report
While the global incidence of esophageal cancer has increased, so too have the numbers of…
Markets
more-
Weekly Market Review – November 2, 2024
Stock Markets All the major indexes are down for this week. The 30-stock Dow Jones…
Bio Space
more
OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs
OS Therapies will list on the NYSE American stock exchange…
IRA drug price reductions won’t hurt biotech innovation, analyses find
Since its passage in August 2022, the Inflation Reduction Act…
Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential
We already know that Takeda is hoping to find a…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
As esophageal cancer incidence rises, trials and potential treatments burgeon: Novotech report
The FDA is hiring. Wanted: One (1) CDRH Director
Stryker tucks in breast tumor marker maker amid ‘bullish’ M&A pipeline
AC Immune claims new class of Alzheimer’s-focused ADC has ‘landmark’ CNS potential
OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs
IRA drug price reductions won’t hurt biotech innovation, analyses find
Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential
Ideaya, eyeing drug combos, bags option on Biocytogen bispecific ADC in $400M deal
GSK drops phase 2 HPV vaccine over lack of best-in-class potential
inFormed launches program to send clinical trial consent to patient phones